• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mirum Pharmaceuticals Inc (NQ: MIRM )

    40.72 UNCHANGED
    Streaming Delayed Price Updated: 4:15 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Mirum Pharmaceuticals Inc

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Where Mirum Pharmaceuticals Stands With Analysts
    Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings: 
    Via Benzinga
    Robinhood, MicroStrategy And Other Big Losers From Wednesday
    U.S. stocks closed lower on Wednesday, with the Dow Jones dipping more than 600 points. Here is the list of some big stocks recording losses in the previous session. 
    Via Benzinga
    Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Recap: Mirum Pharmaceuticals Q2 Earnings
    Mirum Pharmaceuticals (NASDAQ:MIRM) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
    Gainers 
    Via Benzinga
    Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
    Gainers 
    Via Benzinga
    Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum’s LIVMARLI Data Featured in Two Late-Breaker Presentations at The Liver Meeting of the American Association for the Study of Liver Diseases
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday
    Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company. 
    Via Benzinga
    Analysts Expect Mirum Pharma's Liver Disease Candidate Might Exceed Rival Product's Penetration
    Via Benzinga
    Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals’ LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual Meeting
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals to Present LIVMARLI® (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual Meeting
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
    Upgrades 
    Via Benzinga
    Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    'It Is Too Sizzling For Me': Why Jim Cramer Isn't Buying This 'Red Hot' Group Of Stocks
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said Kelly Services, Inc. (NASDAQ: KELYA) is a "very well-run company. Right now, with people just feeling it’s easy to get a job, you don’t need them.... 
    Via Benzinga
    Looking Into Mirum Pharmaceuticals's Return On Capital Employed
    According to Benzinga Pro data, during Q2, Mirum Pharmaceuticals (NASDAQ:MIRM) posted sales of $17.48 million. Earnings were up 26.45%, but Mirum Pharmaceuticals still reported an overall loss of... 
    Via Benzinga
    Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Here's Why Mirum Pharmaceuticals Stock Is Getting Hammered
    Mirum Pharmaceuticals Inc (NASDAQ: MIRM) shares are trading lower by 13.46% to $23.79 Wednesday afternoon after the company priced its common stock offering of 3.478 million shares at $23 per share.... 
    Via Benzinga
    Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.